COVID‐SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults
BACKGROUND/OBJECTIVES Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection causes high morbidity and mortality in older adults with chronic illnesses. Several trials are currently underway evaluating the antimalarial drug hydroxychloroquine as a potential treatment for acute infect...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Geriatrics Society (JAGS) 2020-08, Vol.68 (8), p.1636-1646 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1646 |
|---|---|
| container_issue | 8 |
| container_start_page | 1636 |
| container_title | Journal of the American Geriatrics Society (JAGS) |
| container_volume | 68 |
| creator | Ross, Sydney B. Wilson, Marnie Goodwin Papillon‐Ferland, Louise Elsayed, Sarah Wu, Peter E. Battu, Kiran Porter, Sandra Rashidi, Babak Tamblyn, Robyn Pilote, Louise Downar, James Bonnici, Andre Huang, Allen Lee, Todd C. McDonald, Emily G. |
| description | BACKGROUND/OBJECTIVES
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection causes high morbidity and mortality in older adults with chronic illnesses. Several trials are currently underway evaluating the antimalarial drug hydroxychloroquine as a potential treatment for acute infection. However, polypharmacy predisposes patients to increased risk of drug‐drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials. We aimed to quantify the degree of polypharmacy and burden of potentially inappropriate medications (PIMs) that older hospitalized adults are taking that would interact with hydroxychloroquine.
METHODS
We reanalyzed data from the cohort of patients 65 years and older enrolled in the MedSafer pilot study. We first identified patients taking medications with potentially harmful drug‐drug interactions with hydroxychloroquine that might exclude them from participation in a typical 2019 coronavirus disease (COVID‐19) therapeutic trial. Next, we identified medications that were flagged by MedSafer as potentially inappropriate and crafted guidance around medication management if contemplating the use of hydroxychloroquine.
RESULTS
The cohort contained a total of 1,001 unique patients with complete data on their home medications at admission. Of these 1,001 patients, 590 (58.9%) were receiving one or more home medications that could potentially interact with hydroxychloroquine, and of these, 255 (43.2%) were flagged as potentially inappropriate by the MedSafer tool. Common classes of PIMs observed were antipsychotics, cardiac medications, and antidiabetic agents.
CONCLUSION
The COVID‐19 pandemic highlights the importance of medication optimization and deprescribing PIMs in older adults. By acting now to reduce polypharmacy and use of PIMs, we can better prepare this vulnerable population for inclusion in trials and, if substantiated, pharmacologic treatment or prevention of COVID‐19. J Am Geriatr Soc 68:1636‐1646, 2020. |
| doi_str_mv | 10.1111/jgs.16623 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7280600</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2406308784</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4433-b6e5de1eb5bac073105c2e10d688c0d6e047ce0bf73095f36e4ff1adf3544ea33</originalsourceid><addsrcrecordid>eNp1kcFuEzEQhi0EoqFw4AWQJS7lsO147d11OSBFSZsGVYrUFo5YXu9s6mhjB3u3bW48As_Ik-CSUgESc5g5zKdPM_oJec3gkKU6Wi3jISvLnD8hI1bwPCsEK56SEQDkmSyZ2CMvYlwBsBykfE72eC4Eqyo2Il8mi8_z6Y9v3y_HpycX7-kUNwGjCba2bklng220M0hbH-jZtgn-bmuuOx_818E6pNMwLOnc9Ri06a13kVpHF12DgY6boevjS_Ks1V3EVw9zn3w6PbmanGXni9l8Mj7PjBCcZ3WJRYMM66LWBirOoDA5MmhKKU3qCKIyCHVbcTguWl6iaFumm5YXQqDmfJ982Hk3Q73GxqDrg-7UJti1DlvltVV_b5y9Vkt_o6pcQgmQBAcPgvvfMPZqbaPBrtMO_RBVLqDkICspEvr2H3Tlh-DSe4niXDDJquNEvdtRJvgYA7aPxzBQ96mplJr6lVpi3_x5_SP5O6YEHO2AW9vh9v8m9XF2uVP-BB8AosQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2433418179</pqid></control><display><type>article</type><title>COVID‐SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Ross, Sydney B. ; Wilson, Marnie Goodwin ; Papillon‐Ferland, Louise ; Elsayed, Sarah ; Wu, Peter E. ; Battu, Kiran ; Porter, Sandra ; Rashidi, Babak ; Tamblyn, Robyn ; Pilote, Louise ; Downar, James ; Bonnici, Andre ; Huang, Allen ; Lee, Todd C. ; McDonald, Emily G.</creator><creatorcontrib>Ross, Sydney B. ; Wilson, Marnie Goodwin ; Papillon‐Ferland, Louise ; Elsayed, Sarah ; Wu, Peter E. ; Battu, Kiran ; Porter, Sandra ; Rashidi, Babak ; Tamblyn, Robyn ; Pilote, Louise ; Downar, James ; Bonnici, Andre ; Huang, Allen ; Lee, Todd C. ; McDonald, Emily G.</creatorcontrib><description>BACKGROUND/OBJECTIVES
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection causes high morbidity and mortality in older adults with chronic illnesses. Several trials are currently underway evaluating the antimalarial drug hydroxychloroquine as a potential treatment for acute infection. However, polypharmacy predisposes patients to increased risk of drug‐drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials. We aimed to quantify the degree of polypharmacy and burden of potentially inappropriate medications (PIMs) that older hospitalized adults are taking that would interact with hydroxychloroquine.
METHODS
We reanalyzed data from the cohort of patients 65 years and older enrolled in the MedSafer pilot study. We first identified patients taking medications with potentially harmful drug‐drug interactions with hydroxychloroquine that might exclude them from participation in a typical 2019 coronavirus disease (COVID‐19) therapeutic trial. Next, we identified medications that were flagged by MedSafer as potentially inappropriate and crafted guidance around medication management if contemplating the use of hydroxychloroquine.
RESULTS
The cohort contained a total of 1,001 unique patients with complete data on their home medications at admission. Of these 1,001 patients, 590 (58.9%) were receiving one or more home medications that could potentially interact with hydroxychloroquine, and of these, 255 (43.2%) were flagged as potentially inappropriate by the MedSafer tool. Common classes of PIMs observed were antipsychotics, cardiac medications, and antidiabetic agents.
CONCLUSION
The COVID‐19 pandemic highlights the importance of medication optimization and deprescribing PIMs in older adults. By acting now to reduce polypharmacy and use of PIMs, we can better prepare this vulnerable population for inclusion in trials and, if substantiated, pharmacologic treatment or prevention of COVID‐19. J Am Geriatr Soc 68:1636‐1646, 2020.</description><identifier>ISSN: 0002-8614</identifier><identifier>ISSN: 1532-5415</identifier><identifier>EISSN: 1532-5415</identifier><identifier>DOI: 10.1111/jgs.16623</identifier><identifier>PMID: 32441771</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Aged ; Aged, 80 and over ; Antidiabetics ; Antipsychotics ; Betacoronavirus ; Chronic infection ; Clinical Investigation ; Clinical trials ; Clinical Trials as Topic ; Coronaviridae ; Coronavirus Infections - drug therapy ; Coronaviruses ; COVID-19 ; COVID-19 Drug Treatment ; COVID‐19‐Related Content ; deprescribing ; Deprescriptions ; Diabetes mellitus ; Drug interactions ; Female ; Humans ; Hydroxychloroquine ; Hydroxychloroquine - administration & dosage ; Male ; Morbidity ; Older people ; Pandemics ; Patient Selection ; Pilot Projects ; Pneumonia, Viral - drug therapy ; Polypharmacy ; Potentially Inappropriate Medication List - standards ; potentially inappropriate medications ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2</subject><ispartof>Journal of the American Geriatrics Society (JAGS), 2020-08, Vol.68 (8), p.1636-1646</ispartof><rights>2020 The American Geriatrics Society</rights><rights>2020 The American Geriatrics Society.</rights><rights>2020 American Geriatrics Society and Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4433-b6e5de1eb5bac073105c2e10d688c0d6e047ce0bf73095f36e4ff1adf3544ea33</citedby><cites>FETCH-LOGICAL-c4433-b6e5de1eb5bac073105c2e10d688c0d6e047ce0bf73095f36e4ff1adf3544ea33</cites><orcidid>0000-0003-0783-0624</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjgs.16623$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjgs.16623$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32441771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ross, Sydney B.</creatorcontrib><creatorcontrib>Wilson, Marnie Goodwin</creatorcontrib><creatorcontrib>Papillon‐Ferland, Louise</creatorcontrib><creatorcontrib>Elsayed, Sarah</creatorcontrib><creatorcontrib>Wu, Peter E.</creatorcontrib><creatorcontrib>Battu, Kiran</creatorcontrib><creatorcontrib>Porter, Sandra</creatorcontrib><creatorcontrib>Rashidi, Babak</creatorcontrib><creatorcontrib>Tamblyn, Robyn</creatorcontrib><creatorcontrib>Pilote, Louise</creatorcontrib><creatorcontrib>Downar, James</creatorcontrib><creatorcontrib>Bonnici, Andre</creatorcontrib><creatorcontrib>Huang, Allen</creatorcontrib><creatorcontrib>Lee, Todd C.</creatorcontrib><creatorcontrib>McDonald, Emily G.</creatorcontrib><title>COVID‐SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults</title><title>Journal of the American Geriatrics Society (JAGS)</title><addtitle>J Am Geriatr Soc</addtitle><description>BACKGROUND/OBJECTIVES
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection causes high morbidity and mortality in older adults with chronic illnesses. Several trials are currently underway evaluating the antimalarial drug hydroxychloroquine as a potential treatment for acute infection. However, polypharmacy predisposes patients to increased risk of drug‐drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials. We aimed to quantify the degree of polypharmacy and burden of potentially inappropriate medications (PIMs) that older hospitalized adults are taking that would interact with hydroxychloroquine.
METHODS
We reanalyzed data from the cohort of patients 65 years and older enrolled in the MedSafer pilot study. We first identified patients taking medications with potentially harmful drug‐drug interactions with hydroxychloroquine that might exclude them from participation in a typical 2019 coronavirus disease (COVID‐19) therapeutic trial. Next, we identified medications that were flagged by MedSafer as potentially inappropriate and crafted guidance around medication management if contemplating the use of hydroxychloroquine.
RESULTS
The cohort contained a total of 1,001 unique patients with complete data on their home medications at admission. Of these 1,001 patients, 590 (58.9%) were receiving one or more home medications that could potentially interact with hydroxychloroquine, and of these, 255 (43.2%) were flagged as potentially inappropriate by the MedSafer tool. Common classes of PIMs observed were antipsychotics, cardiac medications, and antidiabetic agents.
CONCLUSION
The COVID‐19 pandemic highlights the importance of medication optimization and deprescribing PIMs in older adults. By acting now to reduce polypharmacy and use of PIMs, we can better prepare this vulnerable population for inclusion in trials and, if substantiated, pharmacologic treatment or prevention of COVID‐19. J Am Geriatr Soc 68:1636‐1646, 2020.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antidiabetics</subject><subject>Antipsychotics</subject><subject>Betacoronavirus</subject><subject>Chronic infection</subject><subject>Clinical Investigation</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Coronaviridae</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 Drug Treatment</subject><subject>COVID‐19‐Related Content</subject><subject>deprescribing</subject><subject>Deprescriptions</subject><subject>Diabetes mellitus</subject><subject>Drug interactions</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxychloroquine</subject><subject>Hydroxychloroquine - administration & dosage</subject><subject>Male</subject><subject>Morbidity</subject><subject>Older people</subject><subject>Pandemics</subject><subject>Patient Selection</subject><subject>Pilot Projects</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Polypharmacy</subject><subject>Potentially Inappropriate Medication List - standards</subject><subject>potentially inappropriate medications</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><issn>0002-8614</issn><issn>1532-5415</issn><issn>1532-5415</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFuEzEQhi0EoqFw4AWQJS7lsO147d11OSBFSZsGVYrUFo5YXu9s6mhjB3u3bW48As_Ik-CSUgESc5g5zKdPM_oJec3gkKU6Wi3jISvLnD8hI1bwPCsEK56SEQDkmSyZ2CMvYlwBsBykfE72eC4Eqyo2Il8mi8_z6Y9v3y_HpycX7-kUNwGjCba2bklng220M0hbH-jZtgn-bmuuOx_818E6pNMwLOnc9Ri06a13kVpHF12DgY6boevjS_Ks1V3EVw9zn3w6PbmanGXni9l8Mj7PjBCcZ3WJRYMM66LWBirOoDA5MmhKKU3qCKIyCHVbcTguWl6iaFumm5YXQqDmfJ982Hk3Q73GxqDrg-7UJti1DlvltVV_b5y9Vkt_o6pcQgmQBAcPgvvfMPZqbaPBrtMO_RBVLqDkICspEvr2H3Tlh-DSe4niXDDJquNEvdtRJvgYA7aPxzBQ96mplJr6lVpi3_x5_SP5O6YEHO2AW9vh9v8m9XF2uVP-BB8AosQ</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Ross, Sydney B.</creator><creator>Wilson, Marnie Goodwin</creator><creator>Papillon‐Ferland, Louise</creator><creator>Elsayed, Sarah</creator><creator>Wu, Peter E.</creator><creator>Battu, Kiran</creator><creator>Porter, Sandra</creator><creator>Rashidi, Babak</creator><creator>Tamblyn, Robyn</creator><creator>Pilote, Louise</creator><creator>Downar, James</creator><creator>Bonnici, Andre</creator><creator>Huang, Allen</creator><creator>Lee, Todd C.</creator><creator>McDonald, Emily G.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0783-0624</orcidid></search><sort><creationdate>202008</creationdate><title>COVID‐SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults</title><author>Ross, Sydney B. ; Wilson, Marnie Goodwin ; Papillon‐Ferland, Louise ; Elsayed, Sarah ; Wu, Peter E. ; Battu, Kiran ; Porter, Sandra ; Rashidi, Babak ; Tamblyn, Robyn ; Pilote, Louise ; Downar, James ; Bonnici, Andre ; Huang, Allen ; Lee, Todd C. ; McDonald, Emily G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4433-b6e5de1eb5bac073105c2e10d688c0d6e047ce0bf73095f36e4ff1adf3544ea33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antidiabetics</topic><topic>Antipsychotics</topic><topic>Betacoronavirus</topic><topic>Chronic infection</topic><topic>Clinical Investigation</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Coronaviridae</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 Drug Treatment</topic><topic>COVID‐19‐Related Content</topic><topic>deprescribing</topic><topic>Deprescriptions</topic><topic>Diabetes mellitus</topic><topic>Drug interactions</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxychloroquine</topic><topic>Hydroxychloroquine - administration & dosage</topic><topic>Male</topic><topic>Morbidity</topic><topic>Older people</topic><topic>Pandemics</topic><topic>Patient Selection</topic><topic>Pilot Projects</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Polypharmacy</topic><topic>Potentially Inappropriate Medication List - standards</topic><topic>potentially inappropriate medications</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ross, Sydney B.</creatorcontrib><creatorcontrib>Wilson, Marnie Goodwin</creatorcontrib><creatorcontrib>Papillon‐Ferland, Louise</creatorcontrib><creatorcontrib>Elsayed, Sarah</creatorcontrib><creatorcontrib>Wu, Peter E.</creatorcontrib><creatorcontrib>Battu, Kiran</creatorcontrib><creatorcontrib>Porter, Sandra</creatorcontrib><creatorcontrib>Rashidi, Babak</creatorcontrib><creatorcontrib>Tamblyn, Robyn</creatorcontrib><creatorcontrib>Pilote, Louise</creatorcontrib><creatorcontrib>Downar, James</creatorcontrib><creatorcontrib>Bonnici, Andre</creatorcontrib><creatorcontrib>Huang, Allen</creatorcontrib><creatorcontrib>Lee, Todd C.</creatorcontrib><creatorcontrib>McDonald, Emily G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the American Geriatrics Society (JAGS)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ross, Sydney B.</au><au>Wilson, Marnie Goodwin</au><au>Papillon‐Ferland, Louise</au><au>Elsayed, Sarah</au><au>Wu, Peter E.</au><au>Battu, Kiran</au><au>Porter, Sandra</au><au>Rashidi, Babak</au><au>Tamblyn, Robyn</au><au>Pilote, Louise</au><au>Downar, James</au><au>Bonnici, Andre</au><au>Huang, Allen</au><au>Lee, Todd C.</au><au>McDonald, Emily G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID‐SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults</atitle><jtitle>Journal of the American Geriatrics Society (JAGS)</jtitle><addtitle>J Am Geriatr Soc</addtitle><date>2020-08</date><risdate>2020</risdate><volume>68</volume><issue>8</issue><spage>1636</spage><epage>1646</epage><pages>1636-1646</pages><issn>0002-8614</issn><issn>1532-5415</issn><eissn>1532-5415</eissn><abstract>BACKGROUND/OBJECTIVES
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection causes high morbidity and mortality in older adults with chronic illnesses. Several trials are currently underway evaluating the antimalarial drug hydroxychloroquine as a potential treatment for acute infection. However, polypharmacy predisposes patients to increased risk of drug‐drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials. We aimed to quantify the degree of polypharmacy and burden of potentially inappropriate medications (PIMs) that older hospitalized adults are taking that would interact with hydroxychloroquine.
METHODS
We reanalyzed data from the cohort of patients 65 years and older enrolled in the MedSafer pilot study. We first identified patients taking medications with potentially harmful drug‐drug interactions with hydroxychloroquine that might exclude them from participation in a typical 2019 coronavirus disease (COVID‐19) therapeutic trial. Next, we identified medications that were flagged by MedSafer as potentially inappropriate and crafted guidance around medication management if contemplating the use of hydroxychloroquine.
RESULTS
The cohort contained a total of 1,001 unique patients with complete data on their home medications at admission. Of these 1,001 patients, 590 (58.9%) were receiving one or more home medications that could potentially interact with hydroxychloroquine, and of these, 255 (43.2%) were flagged as potentially inappropriate by the MedSafer tool. Common classes of PIMs observed were antipsychotics, cardiac medications, and antidiabetic agents.
CONCLUSION
The COVID‐19 pandemic highlights the importance of medication optimization and deprescribing PIMs in older adults. By acting now to reduce polypharmacy and use of PIMs, we can better prepare this vulnerable population for inclusion in trials and, if substantiated, pharmacologic treatment or prevention of COVID‐19. J Am Geriatr Soc 68:1636‐1646, 2020.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>32441771</pmid><doi>10.1111/jgs.16623</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-0783-0624</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-8614 |
| ispartof | Journal of the American Geriatrics Society (JAGS), 2020-08, Vol.68 (8), p.1636-1646 |
| issn | 0002-8614 1532-5415 1532-5415 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7280600 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Aged Aged, 80 and over Antidiabetics Antipsychotics Betacoronavirus Chronic infection Clinical Investigation Clinical trials Clinical Trials as Topic Coronaviridae Coronavirus Infections - drug therapy Coronaviruses COVID-19 COVID-19 Drug Treatment COVID‐19‐Related Content deprescribing Deprescriptions Diabetes mellitus Drug interactions Female Humans Hydroxychloroquine Hydroxychloroquine - administration & dosage Male Morbidity Older people Pandemics Patient Selection Pilot Projects Pneumonia, Viral - drug therapy Polypharmacy Potentially Inappropriate Medication List - standards potentially inappropriate medications SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 |
| title | COVID‐SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T20%3A50%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID%E2%80%90SAFER:%20Deprescribing%20Guidance%20for%20Hydroxychloroquine%20Drug%20Interactions%20in%20Older%20Adults&rft.jtitle=Journal%20of%20the%20American%20Geriatrics%20Society%20(JAGS)&rft.au=Ross,%20Sydney%20B.&rft.date=2020-08&rft.volume=68&rft.issue=8&rft.spage=1636&rft.epage=1646&rft.pages=1636-1646&rft.issn=0002-8614&rft.eissn=1532-5415&rft_id=info:doi/10.1111/jgs.16623&rft_dat=%3Cproquest_pubme%3E2406308784%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2433418179&rft_id=info:pmid/32441771&rfr_iscdi=true |